CO2020002678A2 - Inhibidores macrocíclicos de mcl-1 y métodos de uso - Google Patents
Inhibidores macrocíclicos de mcl-1 y métodos de usoInfo
- Publication number
- CO2020002678A2 CO2020002678A2 CONC2020/0002678A CO2020002678A CO2020002678A2 CO 2020002678 A2 CO2020002678 A2 CO 2020002678A2 CO 2020002678 A CO2020002678 A CO 2020002678A CO 2020002678 A2 CO2020002678 A2 CO 2020002678A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhibitors
- methods
- formula
- mcl
- macrocyclic
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102220480121 H/ACA ribonucleoprotein complex subunit DKC1_R10A_mutation Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación proporciona compuestos de la Fórmula (I) (I), en donde A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X e Y tienen cualquiera de los valores definidos en la memoria descriptiva, y sales aceptables desde el punto de vista farmacéutico de estos, que son útiles como agentes en el tratamiento de enfermedades y afecciones, incluido el cáncer. También se proporcionan composiciones farmacéuticas que comprenden compuestos de la Fórmula (I).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545853P | 2017-08-15 | 2017-08-15 | |
| US201762555475P | 2017-09-07 | 2017-09-07 | |
| US201862692663P | 2018-06-30 | 2018-06-30 | |
| PCT/US2018/000180 WO2019035911A1 (en) | 2017-08-15 | 2018-08-15 | MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020002678A2 true CO2020002678A2 (es) | 2020-08-10 |
Family
ID=65362347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0002678A CO2020002678A2 (es) | 2017-08-15 | 2020-03-10 | Inhibidores macrocíclicos de mcl-1 y métodos de uso |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10676485B2 (es) |
| EP (2) | EP3988555A1 (es) |
| JP (1) | JP2020531433A (es) |
| KR (1) | KR20200041942A (es) |
| CN (1) | CN111818917A (es) |
| AU (1) | AU2018316620A1 (es) |
| BR (1) | BR112020003180A2 (es) |
| CA (1) | CA3073112A1 (es) |
| CL (2) | CL2020000363A1 (es) |
| CO (1) | CO2020002678A2 (es) |
| CR (1) | CR20200124A (es) |
| EC (1) | ECSP20018703A (es) |
| IL (1) | IL272681A (es) |
| MX (1) | MX2020001717A (es) |
| PE (1) | PE20200837A1 (es) |
| PH (1) | PH12020500327A1 (es) |
| RU (1) | RU2020110517A (es) |
| SG (2) | SG11202001182QA (es) |
| TW (1) | TW201920194A (es) |
| UA (1) | UA126586C2 (es) |
| UY (1) | UY37843A (es) |
| WO (1) | WO2019035911A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| TW201920193A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環ｍｅｌ-１抑制劑以及使用方法 |
| US10676485B2 (en) * | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| CN109467538A (zh) | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| MX2020002611A (es) | 2017-09-07 | 2020-07-13 | Univ Res Inst Inc Augusta | Activador especifico de akt3 y usos del mismo. |
| KR20220024106A (ko) | 2019-05-20 | 2022-03-03 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| IL303079A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014627B (zh) * | 2008-04-30 | 2014-10-29 | 国家卫生研究院 | 作为极光激酶抑制剂的稠合双环嘧啶化合物 |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JO3474B1 (ar) * | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037958B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3037957B1 (fr) | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3046792B1 (fr) | 2016-01-19 | 2018-02-02 | Les Laboratoires Servier | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2791319T3 (es) | 2016-04-22 | 2020-11-03 | Astrazeneca Ab | Inhibidores de MCL1 macrocíclicos para tratar el cáncer |
| AU2017300738A1 (en) | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
| AU2017350499B2 (en) | 2016-10-28 | 2023-08-10 | Les Laboratoires Servier | Liposomal formulation for use in the treatment of cancer |
| EP3567043B1 (en) | 2017-01-05 | 2023-12-06 | Henan Genuine Biotech Co., Ltd. | 2-[[5-[(4-hydroxy-3-chloro-2-methyl)-phenyl]-thieno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-methoxybenzene)propanoic acid derivatives as mcl-1 and bcl-2 inhibitors for treating cancer |
| UY37560A (es) | 2017-01-06 | 2018-07-31 | Servier Lab | Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta |
| TW201920193A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環ｍｅｌ-１抑制劑以及使用方法 |
| AU2018317828A1 (en) * | 2017-08-15 | 2020-04-02 | AbbVie Deutschland GmbH & Co. KG | Macrocyclic MCL-1 inhibitors and methods of use |
| US10676485B2 (en) * | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| CN107573360B (zh) | 2017-10-27 | 2019-08-09 | 都创(上海)医药科技有限公司 | 一种多靶点小分子化合物s63845的制备方法 |
-
2018
- 2018-08-15 US US15/998,789 patent/US10676485B2/en active Active
- 2018-08-15 KR KR1020207007568A patent/KR20200041942A/ko not_active Ceased
- 2018-08-15 CN CN201880066986.9A patent/CN111818917A/zh active Pending
- 2018-08-15 BR BR112020003180-1A patent/BR112020003180A2/pt not_active IP Right Cessation
- 2018-08-15 SG SG11202001182QA patent/SG11202001182QA/en unknown
- 2018-08-15 CR CR20200124A patent/CR20200124A/es unknown
- 2018-08-15 AU AU2018316620A patent/AU2018316620A1/en not_active Abandoned
- 2018-08-15 RU RU2020110517A patent/RU2020110517A/ru unknown
- 2018-08-15 CA CA3073112A patent/CA3073112A1/en active Pending
- 2018-08-15 UA UAA202001749A patent/UA126586C2/uk unknown
- 2018-08-15 MX MX2020001717A patent/MX2020001717A/es unknown
- 2018-08-15 EP EP21197248.4A patent/EP3988555A1/en active Pending
- 2018-08-15 SG SG10202106345VA patent/SG10202106345VA/en unknown
- 2018-08-15 JP JP2020508463A patent/JP2020531433A/ja active Pending
- 2018-08-15 EP EP18846737.7A patent/EP3652184A4/en not_active Withdrawn
- 2018-08-15 UY UY0001037843A patent/UY37843A/es not_active Application Discontinuation
- 2018-08-15 WO PCT/US2018/000180 patent/WO2019035911A1/en not_active Ceased
- 2018-08-15 PE PE2020000240A patent/PE20200837A1/es unknown
- 2018-08-15 TW TW107128523A patent/TW201920194A/zh unknown
-
2020
- 2020-02-12 CL CL2020000363A patent/CL2020000363A1/es unknown
- 2020-02-13 PH PH12020500327A patent/PH12020500327A1/en unknown
- 2020-02-14 IL IL272681A patent/IL272681A/en unknown
- 2020-03-10 CO CONC2020/0002678A patent/CO2020002678A2/es unknown
- 2020-03-13 EC ECSENADI202018703A patent/ECSP20018703A/es unknown
- 2020-05-11 US US16/872,279 patent/US20200325153A1/en not_active Abandoned
- 2020-11-12 CL CL2020002943A patent/CL2020002943A1/es unknown
-
2022
- 2022-02-03 US US17/649,906 patent/US20230183261A1/en not_active Abandoned
-
2024
- 2024-02-29 US US18/592,020 patent/US20250092062A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10676485B2 (en) | 2020-06-09 |
| WO2019035911A1 (en) | 2019-02-21 |
| RU2020110517A (ru) | 2021-09-16 |
| SG11202001182QA (en) | 2020-03-30 |
| UY37843A (es) | 2019-03-29 |
| PH12020500327A1 (en) | 2020-10-12 |
| US20190144465A1 (en) | 2019-05-16 |
| JP2020531433A (ja) | 2020-11-05 |
| EP3652184A1 (en) | 2020-05-20 |
| CA3073112A1 (en) | 2019-02-21 |
| IL272681A (en) | 2020-03-31 |
| US20200325153A1 (en) | 2020-10-15 |
| KR20200041942A (ko) | 2020-04-22 |
| RU2020110517A3 (es) | 2022-03-23 |
| CL2020002943A1 (es) | 2021-03-12 |
| CR20200124A (es) | 2020-09-28 |
| BR112020003180A2 (pt) | 2020-09-15 |
| EP3652184A4 (en) | 2020-05-20 |
| ECSP20018703A (es) | 2020-04-22 |
| TW201920194A (zh) | 2019-06-01 |
| US20250092062A1 (en) | 2025-03-20 |
| PE20200837A1 (es) | 2020-08-13 |
| SG10202106345VA (en) | 2021-07-29 |
| US20230183261A1 (en) | 2023-06-15 |
| EP3988555A1 (en) | 2022-04-27 |
| MX2020001717A (es) | 2020-10-08 |
| CN111818917A (zh) | 2020-10-23 |
| UA126586C2 (uk) | 2022-11-02 |
| AU2018316620A1 (en) | 2020-03-12 |
| CL2020000363A1 (es) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20018703A (es) | Inhibidores macrocíclicos de mcl-1 y métodos de uso | |
| MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
| UY37842A (es) | Inhibidores de mcl-1 macrocíclicos y métodos de uso | |
| DOP2022000117A (es) | Inhibidores de kras g12c | |
| UY39630A (es) | Inhibidores de bromodominios | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| MX2016011468A (es) | Inhibidores de calicreína plasmática humana. | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| MX2022002976A (es) | Inhibidores selectivos de jak1. | |
| MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
| PE20151788A1 (es) | Inhibidores de bromodominios tetraciclicos | |
| MX2016013052A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CO2018004572A2 (es) | Inhibidores de calicreína plasmática humana | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CY1121060T1 (el) | Παραγωγα [1,2,4] τριαζολο[1,5-α] πυριμιδινης ως αναστολεις πρωτεασωματος πρωτοζωων για τη θεραπεια παρασιτικων νοσηματων οπως η λεϊσμανιαση | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| UY36123A (es) | Derivados de carboxamida | |
| EA201792265A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| CU20160170A7 (es) | Derivados de carboxamida |